This Article Full Text Full Text (PDF) All Versions of this Article: 37/5/1227    most recent 01.STR.0000217403.66996.6dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furlan, A. J. Search for Related Content PubMed PubMed Citation Articles by Furlan, A. J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Thrombolysis

(Stroke. 2006;37:1227.)
© 2006 American Heart Association, Inc.

Original Contributions

Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS)

Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset

Anthony J. Furlan, MD; Dirk Eyding, PhD; Gregory W. Albers, MD; Yasir Al-Rawi, MD; Kennedy R. Lees, MD; Howard A. Rowley, MD; Christian Sachara; Mariola Soehngen, MD; Steven Warach, MD, PhD; Werner Hacke, MD for the DEDAS Investigators

From The Cleveland Clinic (A.F.), Department of Neurology, Cleveland, Ohio; PAION Deutschland GmbH (D.E., Y.A.-R., M.S.), Aachen, Germany; the Stanford Stroke Center (G.A.), Palo Alto, Calif; the Western Infirmery (K.R.L.), University Department of Medicine & Therapeutics, Glasgow, United Kingdom; the University of Wisconsin (H.A.R.), Department of Radiology, Madison, Wis; the ClinResearch GmbH (C.S.), Köln, Germany; the NINDS (S.W.), Bethesda, Md; and the Department of Neurology (W.H.), University of Heidelberg, Heidelberg, Germany.

Correspondence to Anthony J. Furlan, MD, The Cleveland Clinic, Department of Neurology, S91, 9500 Euclid Ave, Cleveland, OH 44195, USA. E-mail furlana{at}ccf.org

Background and Purpose— Desmoteplase is a novel plasminogen activator with favorable features in vitro compared with available agents. This study evaluated safety and efficacy of intravenous (IV) desmoteplase in patients with perfusion/diffusion mismatch on MRI 3 to 9 hours after onset of acute ischemic stroke.

Methods— DEDAS was a placebo-controlled, double-blind, randomized, dose-escalation study investigating doses of 90 µg/kg and 125 µg/kg desmoteplase. Eligibility criteria included baseline National Institute of Health Stroke Scale (NIHSS) scores of 4 to 20 and MRI evidence of perfusion/diffusion mismatch. The safety end point was the rate of symptomatic intracranial hemorrhage. Primary efficacy co-end points were MRI reperfusion 4 to 8 hours after treatment and good clinical outcome at 90 days. The primary analyses were intent-to-treat. Before unblinding, a target population, excluding patients violating specific MRI criteria, was defined.

Results— Thirty-seven patients were randomized and received treatment (intent-to-treat; placebo: n=8; 90 µg/kg: n=14; 125 µg/kg: n=15). No symptomatic intracranial hemorrhage occurred. Reperfusion was achieved in 37.5% (95% CI [8.5; 75.5]) of placebo patients, 18.2% (2.3; 51.8) of patients treated with 90 µg/kg desmoteplase, and 53.3% (26.6; 78.7) of patients treated with 125 µg/kg desmoteplase. Good clinical outcome at 90 days occurred in 25.0% (3.2; 65.1) treated with placebo, 28.6% (8.4; 58.1) treated with 90 µg/kg desmoteplase and 60.0% (32.3; 83.7) treated with 125 µg/kg desmoteplase. In the target population (n=25), the difference compared with placebo increased and was statistically significant for good clinical outcome with 125 µg/kg desmoteplase (P=0.022).

Conclusions— Treatment with IV desmoteplase 3 to 9 hours after ischemic stroke onset appears safe. At a dose of 125 µg/kg desmoteplase appeared to improve clinical outcome, especially in patients fulfilling all MRI criteria. The results of DEDAS generally support the results of its predecessor study, Desmoteplase in Acute Ischemic Stroke (DIAS).

Key Words: desmoteplase • stroke • thrombolytic therapy

This article has been cited by other articles:

				J. G. Merino, L. L. Latour, L. An, A. W. Hsia, D.-W. Kang, and S. Warach Reperfusion Half-Life: A Novel Pharmacodynamic Measure of Thrombolytic Activity Stroke, July 1, 2008; 39(7): 2148 - 2150. [Abstract] [Full Text] [PDF]

				I. R. Konig, A. Ziegler, E. Bluhmki, W. Hacke, P. M.W. Bath, R. L. Sacco, H. C. Diener, C. Weimar, and on behalf of the Virtual International Stroke Tria Predicting Long-Term Outcome After Acute Ischemic Stroke: A Simple Index Works in Patients From Controlled Clinical Trials Stroke, June 1, 2008; 39(6): 1821 - 1826. [Abstract] [Full Text] [PDF]

				S. Yoshida, T. Sudo, M. Niimi, L. Tao, B. Sun, J. Kambayashi, H. Watanabe, E. Luo, and H. Matsuoka Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito Blood, February 15, 2008; 111(4): 2007 - 2014. [Abstract] [Full Text] [PDF]

				S. A. Mayer and S. Schwab Advances in Critical Care and Emergency Medicine 2007 Stroke, February 1, 2008; 39(2): 261 - 263. [Full Text] [PDF]

				J. Juhl Majersik, M. A. Smith, D. B. Zahuranec, B. N. Sanchez, and L. B. Morgenstern Population-Based Analysis of the Impact of Expanding the Time Window for Acute Stroke Treatment Stroke, December 1, 2007; 38(12): 3213 - 3217. [Abstract] [Full Text] [PDF]

				M. Kaste Do Not Wait, Act Now Stroke, December 1, 2007; 38(12): 3119 - 3120. [Full Text] [PDF]

				J. G. Merino, L. L. Latour, J. W. Todd, M. Luby, P. D. Schellinger, D.-W. Kang, and S. Warach Lesion Volume Change After Treatment With Tissue Plasminogen Activator Can Discriminate Clinical Responders From Nonresponders Stroke, November 1, 2007; 38(11): 2919 - 2923. [Abstract] [Full Text] [PDF]

				M. Luby and S. Warach Reliability of MR Perfusion-Weighted and Diffusion-Weighted Imaging Mismatch Measurement Methods AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1674 - 1678. [Abstract] [Full Text] [PDF]

				P. D. Schellinger, G. Thomalla, J. Fiehler, M. Kohrmann, C. A. Molina, T. Neumann-Haefelin, M. Ribo, O. C. Singer, O. Zaro-Weber, and J. Sobesky MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows: An Analysis of 1210 Patients Stroke, October 1, 2007; 38(10): 2640 - 2645. [Abstract] [Full Text] [PDF]

				A. Ogawa, E. Mori, K. Minematsu, W. Taki, A. Takahashi, S. Nemoto, S. Miyamoto, M. Sasaki, T. Inoue, and for The MELT Japan Study Group Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan Stroke, October 1, 2007; 38(10): 2633 - 2639. [Abstract] [Full Text] [PDF]

				C. Foerch, M. T. Wunderlich, F. Dvorak, M. Humpich, T. Kahles, M. Goertler, J. Alvarez-Sabin, C. W. Wallesch, C. A. Molina, H. Steinmetz, et al. Elevated Serum S100B Levels Indicate a Higher Risk of Hemorrhagic Transformation After Thrombolytic Therapy in Acute Stroke Stroke, September 1, 2007; 38(9): 2491 - 2495. [Abstract] [Full Text] [PDF]

				K. Nedeltchev, B. Schwegler, T. Haefeli, C. Brekenfeld, J. Gralla, U. Fischer, M. Arnold, L. Remonda, G. Schroth, and H. P. Mattle Outcome of Stroke With Mild or Rapidly Improving Symptoms Stroke, September 1, 2007; 38(9): 2531 - 2535. [Abstract] [Full Text] [PDF]

				K. W. Muir, J. Baird-Gunning, L. Walker, T. Baird, M. McCormick, and S. B. Coutts Can the Ischemic Penumbra Be Identified on Noncontrast CT of Acute Stroke? Stroke, September 1, 2007; 38(9): 2485 - 2490. [Abstract] [Full Text] [PDF]

				R. Kollmar and S. Schwab Ischaemic stroke: acute management, intensive care, and future perspectives Br. J. Anaesth., July 1, 2007; 99(1): 95 - 101. [Abstract] [Full Text] [PDF]

				S. R. Messe, S. E. Kasner, J. A. Chalela, B. Cucchiara, A. M. Demchuk, M. D. Hill, and S. Warach CT-NIHSS Mismatch Does Not Correlate With MRI Diffusion-Perfusion Mismatch Stroke, July 1, 2007; 38(7): 2079 - 2084. [Abstract] [Full Text] [PDF]

				M. H. Lev CT/NIHSS Mismatch for Detection of Salvageable Brain in Acute Stroke Triage Beyond the 3-Hour Time Window: Overrated or Undervalued? Stroke, July 1, 2007; 38(7): 2028 - 2029. [Full Text] [PDF]

				R. L. DeLaPaz and for the Expert Panel on Neurologic Imaging Cerebrovascular Disease AJNR Am. J. Neuroradiol., June 1, 2007; 28(6): 1197 - 1199. [Full Text] [PDF]

				M. G. Lansberg, V. N. Thijs, S. Hamilton, G. Schlaug, R. Bammer, S. Kemp, G. W. Albers, and on behalf of the DEFUSE Investigators Evaluation of the Clinical-Diffusion and Perfusion-Diffusion Mismatch Models in DEFUSE Stroke, June 1, 2007; 38(6): 1826 - 1830. [Abstract] [Full Text] [PDF]

				E. B. Milbrandt, A. Ishizaka, and D. C. Angus Update in Critical Care 2006 Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 638 - 648. [Full Text] [PDF]

				J. P. Lopez-Atalaya, B. D. Roussel, C. Ali, E. Maubert, K.-U. Petersen, V. Berezowski, R. Cecchelli, C. Orset, and D. Vivien Recombinant Desmodus rotundus Salivary Plasminogen Activator Crosses the Blood-Brain Barrier Through a Low-Density Lipoprotein Receptor-Related Protein-Dependent Mechanism Without Exerting Neurotoxic Effects Stroke, March 1, 2007; 38(3): 1036 - 1043. [Abstract] [Full Text] [PDF]

				K. R. Lees and J. Dawson Advances in Emerging Therapies 2006 Stroke, February 1, 2007; 38(2): 219 - 221. [Full Text] [PDF]

				W.-D. Heiss and A. G. Sorensen Advances in Imaging 2006 Stroke, February 1, 2007; 38(2): 238 - 240. [Full Text] [PDF]

				K. Nedeltchev, U. Fischer, M. Arnold, P. Ballinari, T. Haefeli, L. Kappeler, C. Brekenfeld, L. Remonda, G. Schroth, and H. P. Mattle Long-Term Effect of Intra-Arterial Thrombolysis in Stroke Stroke, December 1, 2006; 37(12): 3002 - 3007. [Abstract] [Full Text] [PDF]

				J. Dawson and M. Walters New and emerging treatments for stroke Br. Med. Bull., November 7, 2006; (2006) ldl011v1. [Abstract] [Full Text] [PDF]

				A. Srinivasan, M. Goyal, F. A. Azri, and C. Lum State-of-the-Art Imaging of Acute Stroke RadioGraphics, October 1, 2006; 26(suppl_1): S75 - S95. [Abstract] [Full Text] [PDF]

				M.D. Hill, A.M. Demchuk, T.A. Tomsick, Y.Y. Palesch, J.P. Broderick, and on behalf of the IMS-1 Investigators Using the Baseline CT Scan to Select Acute Stroke Patients for IV-IA Therapy. AJNR Am. J. Neuroradiol., September 1, 2006; 27(8): 1612 - 1616. [Abstract] [Full Text] [PDF]

				L. R. Caplan Stroke Thrombolysis: Slow Progress Circulation, July 18, 2006; 114(3): 187 - 190. [Full Text] [PDF]